Novo Nordisk Partners With OpenAI to Accelerate Drug Development

Drugmaker Novo Nordisk said April 14 it is partnering with OpenAI to apply artificial intelligence across drug discovery and business operations.

The company said the collaboration will use advanced AI to analyze complex datasets, identify drug candidates, and reduce the time required to move treatments from research to patient use, according to its official announcement.

Novo said the partnership will integrate OpenAI’s AI capabilities across its global operations, including research, manufacturing, supply chain, distribution, and commercial functions.

Chief Executive Officer Mike Doustdar said the company is applying AI to improve how it discovers and develops treatments. He said the technology allows researchers to analyze data at a larger scale, identify patterns, and test hypotheses more quickly.